关键词: 玛巴洛沙韦, 奥司他韦, 12–18周岁, 流感儿童

Abstract:

This study analyzed case and prescription data of children aged 12 to 18 years diagnosed with influenza A from the outpatient and emergency departments at the Women and Children’s Hospital of Ningbo University during the influenza epidemic period between February and April 2023. Patients were categorized into two groups based on their medication: the Baloxavir Marboxil group (196 cases) and the Oseltamivir group (126 cases). SPSS Statistics 24.0 software was utilized to compare variables between the two groups, including age, sex, weight, first visit department, number of visits, average prescription cost per patient, drug varieties used, hospitalization rate, and the combined medication usage, to evaluate the relative advantages and disadvantages of the two treatments. The results indicated that the number of visits in the Baloxavir Marboxil group was significantly lower than in the Oseltamivir group, whereas the average prescription cost per patient was higher (P < 0.05). There were no significant differences between the two groups regarding age, sex, weight, first visit department, number of drug types used, hospitalization rate, or combined medication usage (P > 0.05). When comparing the use of single-class combined drugs, only the quantity of antiviral drugs differed significantly (P < 0.05). The Oseltamivir group required more adjuvant treatment with both Chinese and Western antiviral medications. The distribution of the number of combined drug types was concentrated around three and two types in both groups (Baloxavir Marboxil group: 41.34% and 39.66%; Oseltamivir group: 44.54% and 36.97%). This study highlighted that the new drug, Baloxavir Marboxil, offered certain therapeutic benefits over Oseltamivir in treating influenza among children aged 12 to 18 years, including advantages in single-dose administration, oral compliance, and specific treatment outcomes. The higher unit cost associated with Baloxavir Marboxil might be a factor for further consideration. These findings provided a new reference point for the clinical selection of anti-influenza medications.

Key words: Baloxavir Marboxil, Oseltamivir, 12–18 years old, Influenza children